ArticleExperimental and therapeutic medicine2026
Tumor-associated macrophages suppress estrogen receptor-β expression in triple-negative breast cancer through the PI3K/AKT pathway.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited therapeutic options. Estrogen receptor (ER)-β exerts anti-tumor effects. However, ERβ expression is frequently reduced in TNBC and the mechanisms underlying the downregulation of ERβ in TNBC remain poorly understood. In the present study, findings revealed that tumor-associated macrophages (TAMs), which are abundant in the tumor microenvironment, suppressed ERβ expression in TNBC cells. The relationship between TAMs and ERβ in TNBC was investigated through bioinformatics analysis, co-culture and orthotopic mouse models. ERβ expression levels were lower in the TNBC tumors compared with normal tissues. Mechanistically, TAM-induced activation of the PI3K/AKT pathway suppressed ERβ expression by reducing FOXO3a binding to the ESR2 promoter, whereas inhibition of PI3K/AKT restored ERβ expression. Notably, combined PI3K/AKT pathway inhibition with ERβ activation attenuated TNBC cell metastasis. Overall, findings indicated that TAMs promoted TNBC progression by downregulating ERβ expression through the PI3K/AKT/FOXO3a axis, highlighting the therapeutic potential of combining PI3K/AKT inhibitors with ERβ agonists in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.